Proving her illness created an illusion of wellness for columnist Ahna Crum, but a relapse after nine years showed her she ...

Exclusive: Scientists uncovered biological strands using artificial intelligence and hope discovery will revolutionise treatment ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

Breakthrough MS study identifies two new types in hopes for treatment - Two new sub-types of multiple sclerosis (MS) were ...

—To some extent, yes, say the results of a recent systematic review and meta-analysis. But were escalation therapies any more effective than platform therapies in boosting cognition? Share on Facebook ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Results from the EVOLVE-MS-1 study show ...

This publication was sponsored and written in partnership with Bristol-Myers Squibb. The American Journal of Managed Care ®: What are some specific patient characteristics associated with ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple ...

The novel drug vidofludimus calcium (Immunic Therapeutics) is safe and effective for patients with relapsing-remitting multiple sclerosis (RRMS), new research suggests. Vidofludimus calcium is an ...

An agent biologically similar to the humanized monoclonal antibody natalizumab is as effective and safe as the original reference drug for relapsing-remitting multiple sclerosis (RRMS) — and has a ...

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...